Literature DB >> 18173231

Positive and negative modulation of group I metabotropic glutamate receptors.

Maksims Vanejevs1, Claudia Jatzke, Steffen Renner, Sibylle Müller, Mirko Hechenberger, Tanja Bauer, Anna Klochkova, Ilya Pyatkin, Denis Kazyulkin, Elena Aksenova, Sergey Shulepin, Olga Timonina, Ariane Haasis, Aleksandrs Gutcaits, Christopher G Parsons, Valerjans Kauss, Tanja Weil.   

Abstract

A discriminating pharmacophore model for noncompetitive metabotropic glutamate receptor antagonists of subtype 1 (mGluR1) was developed that facilitated the discovery of moderately active mGluR1 antagonists. One scaffold was selected for the design of several focused libraries where different substitution patterns were introduced. This approach facilitated the discovery of potent mGluR1 antagonists, as well as positive and negative mGluR5 modulators, because both receptor subtypes share similar binding pockets. For mGluR1 antagonists, a homology model of the mGlu1 receptor was established, and a putative binding mode within the receptor's transmembrane domain was visualized.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18173231     DOI: 10.1021/jm0611298

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  16 in total

Review 1.  Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5).

Authors:  Shaun R Stauffer
Journal:  ACS Chem Neurosci       Date:  2011-06-27       Impact factor: 4.418

Review 2.  Recent advances in the medicinal chemistry of the metabotropic glutamate receptor 1 (mGlu₁).

Authors:  Dafydd R Owen
Journal:  ACS Chem Neurosci       Date:  2011-03-10       Impact factor: 4.418

3.  Exploration of allosteric agonism structure-activity relationships within an acetylene series of metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulators (PAMs): discovery of 5-((3-fluorophenyl)ethynyl)-N-(3-methyloxetan-3-yl)picolinamide (ML254).

Authors:  Mark Turlington; Meredith J Noetzel; Aspen Chun; Ya Zhou; Rocco D Gogliotti; Elizabeth D Nguyen; Karen J Gregory; Paige N Vinson; Jerri M Rook; Kiran K Gogi; Zixiu Xiang; Thomas M Bridges; J Scott Daniels; Carrie Jones; Colleen M Niswender; Jens Meiler; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  J Med Chem       Date:  2013-10-09       Impact factor: 7.446

4.  Synthesis and SAR of centrally active mGlu5 positive allosteric modulators based on an aryl acetylenic bicyclic lactam scaffold.

Authors:  Richard Williams; Jason T Manka; Alice L Rodriguez; Paige N Vinson; Colleen M Niswender; C David Weaver; Carrie K Jones; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2011-01-18       Impact factor: 2.823

5.  Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.

Authors:  Andrzej Dekundy; Andreas Gravius; Mirko Hechenberger; Małgorzata Pietraszek; Jens Nagel; Carsten Tober; Martine van der Elst; Flora Mela; Christopher G Parsons; Wojciech Danysz
Journal:  J Neural Transm (Vienna)       Date:  2010-12-16       Impact factor: 3.575

Review 6.  Allosteric modulation of metabotropic glutamate receptors.

Authors:  Douglas J Sheffler; Karen J Gregory; Jerri M Rook; P Jeffrey Conn
Journal:  Adv Pharmacol       Date:  2011

7.  Development of 1H-Pyrazolo[3,4-b]pyridines as Metabotropic Glutamate Receptor 5 Positive Allosteric Modulators.

Authors:  Matthew D Hill; Haiquan Fang; Jeffrey M Brown; Thaddeus Molski; Amy Easton; Xiaojun Han; Regina Miller; Melissa Hill-Drzewi; Lizbeth Gallagher; Michele Matchett; Michael Gulianello; Anand Balakrishnan; Robert L Bertekap; Kenneth S Santone; Valerie J Whiterock; Xiaoliang Zhuo; Joanne J Bronson; John E Macor; Andrew P Degnan
Journal:  ACS Med Chem Lett       Date:  2016-10-03       Impact factor: 4.345

8.  Discovery and SAR of a novel series of metabotropic glutamate receptor 5 positive allosteric modulators with high ligand efficiency.

Authors:  Mark Turlington; Meredith J Noetzel; Thomas M Bridges; Paige N Vinson; Thomas Steckler; Hilde Lavreysen; Claire Mackie; José M Bartolomé-Nebreda; Susana Conde-Ceide; Han Min Tong; Gregor J Macdonald; J Scott Daniels; Carrie K Jones; Colleen M Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2014-05-02       Impact factor: 2.823

9.  N-aryl piperazine metabotropic glutamate receptor 5 positive allosteric modulators possess efficacy in preclinical models of NMDA hypofunction and cognitive enhancement.

Authors:  K J Gregory; E J Herman; A J Ramsey; A S Hammond; N E Byun; S R Stauffer; J T Manka; S Jadhav; T M Bridges; C D Weaver; C M Niswender; T Steckler; W H Drinkenburg; A Ahnaou; H Lavreysen; G J Macdonald; J M Bartolomé; C Mackie; B J Hrupka; M G Caron; T L Daigle; C W Lindsley; P J Conn; C K Jones
Journal:  J Pharmacol Exp Ther       Date:  2013-08-21       Impact factor: 4.030

10.  Investigating metabotropic glutamate receptor 5 allosteric modulator cooperativity, affinity, and agonism: enriching structure-function studies and structure-activity relationships.

Authors:  Karen J Gregory; Meredith J Noetzel; Jerri M Rook; Paige N Vinson; Shaun R Stauffer; Alice L Rodriguez; Kyle A Emmitte; Ya Zhou; Aspen C Chun; Andrew S Felts; Brian A Chauder; Craig W Lindsley; Colleen M Niswender; P Jeffrey Conn
Journal:  Mol Pharmacol       Date:  2012-08-03       Impact factor: 4.436

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.